Impact Snapshot
Key Metric 1
Multiple NHS drug approvals secured in 2025 including world-first BVD approval, benefitting thousands of myeloma patients
IsaVRD quadruplet treatment approved in England, Wales and Scotland — 63% of patients still in remission after five years in trials